Bank of Montreal Can grew its position in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 8.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,077,081 shares of the biopharmaceutical company's stock after acquiring an additional 82,449 shares during the quarter. Bank of Montreal Can owned about 0.82% of Dynavax Technologies worth $11,848,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of DVAX. GAMMA Investing LLC increased its position in Dynavax Technologies by 175.5% in the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 1,685 shares during the period. US Bancorp DE grew its stake in shares of Dynavax Technologies by 291.4% in the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 2,034 shares during the last quarter. Capital Performance Advisors LLP acquired a new position in shares of Dynavax Technologies in the third quarter valued at approximately $45,000. Nisa Investment Advisors LLC raised its stake in shares of Dynavax Technologies by 44.6% during the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company's stock worth $61,000 after purchasing an additional 1,679 shares during the last quarter. Finally, Algert Global LLC acquired a new stake in shares of Dynavax Technologies during the second quarter worth $140,000. 96.96% of the stock is owned by institutional investors and hedge funds.
Dynavax Technologies Price Performance
Shares of DVAX traded up $0.18 during mid-day trading on Monday, hitting $13.04. The company's stock had a trading volume of 2,689,840 shares, compared to its average volume of 2,154,989. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a 1-year low of $9.74 and a 1-year high of $15.01. The firm has a market capitalization of $1.71 billion, a P/E ratio of 100.32 and a beta of 1.34. The firm has a 50-day simple moving average of $11.69 and a 200 day simple moving average of $11.40.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on DVAX. HC Wainwright reissued a "buy" rating and issued a $29.00 price objective on shares of Dynavax Technologies in a research note on Friday, November 8th. The Goldman Sachs Group lowered their target price on shares of Dynavax Technologies from $20.00 to $15.00 and set a "neutral" rating on the stock in a report on Thursday, August 8th.
Read Our Latest Stock Analysis on DVAX
About Dynavax Technologies
(
Free Report)
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Featured Articles
Before you consider Dynavax Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.
While Dynavax Technologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
